News headlines about Bristol-Myers Squibb (NYSE:BMY) have trended positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.5220297601687 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- BMY INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Bristol-Myers Squibb Company Investors (markets.financialcontent.com)
- Bristol-Myers Squibb (BMY) Announces Clinical Trial Collaboration with TARIS Biomedical LLC (streetinsider.com)
- Bristol-Myers Squibb (BMY) Announces FDA Approval for Opdivo as … – StreetInsider.com (streetinsider.com)
- After Hitting Support, Vetr Issues Buy Rating On Bristol Myers (finance.yahoo.com)
- Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease (finance.yahoo.com)
Shares of Bristol-Myers Squibb (NYSE BMY) traded down $0.54 during mid-day trading on Friday, hitting $60.96. 5,465,510 shares of the company were exchanged, compared to its average volume of 8,315,230. The stock has a market cap of $100,166.05, a PE ratio of 20.68, a P/E/G ratio of 2.32 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb has a 12 month low of $46.01 and a 12 month high of $66.10.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be paid a dividend of $0.40 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.62%. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 61.42%.
BMY has been the subject of a number of recent analyst reports. Jefferies Group reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, September 27th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.50 price objective for the company in a research report on Wednesday, September 27th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $65.00 price objective (up from $62.00) on shares of Bristol-Myers Squibb in a research report on Thursday, September 7th. UBS reaffirmed a “buy” rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Finally, Citigroup upped their price objective on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $64.42.
In other news, Director Theodore R. Samuels II bought 4,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were acquired at an average price of $62.30 per share, with a total value of $249,200.00. Following the acquisition, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.
WARNING: This piece of content was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/22/bristol-myers-squibb-bmy-receiving-favorable-press-coverage-study-shows.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.